Table 1. Demographic characteristics of 330 women aged 15–44 years prescribed sodium valproate between 1 October 2017 and 1 January 2020 in East London.
| Age, yearsa | n (%) |
|---|---|
| 15–19 | 38 (12) |
| 20–24 | 22 (7) |
| 25–29 | 54 (16) |
| 30–34 | 69 (21) |
| 35–39 | 60 (18) |
| ≥40 | 87 (26) |
| Ethnic group a | |
| White | 150 (45) |
| Black | 49 (15) |
| South Asian | 87 (26) |
| Other | 22 (7) |
| Unknown | 22 (7) |
| Received pre-conception or contraception advice b | 151 (46) |
| Prescribed contraception b | 90 (27) |
| Prescribed LARCc | 48 (53) |
| Prescribed non-LARCc | 42 (47) |
| Received advice or contraception b | 191 (58) |
aData relate to most recent record for age and ethnic group. bAt least once during study period. cLong-acting reversible contraception (LARC): copper intrauterine device, levonorgestrel 13.5 mg/19.5 mg/52 mg intrauterine system, and progestogen-only implant. Non-LARC contraception: combined hormonal contraception including combined contraceptive pill, transdermal patch and vaginal ring, progestogen-only pill, progestogen-only injectable depot medroxyprogesterone acetate, condoms, and diaphragms.